Dr.seymour Butts Hemorrhoid Ointment
NDC Package 85248-018-01
Package Information
Dr.seymour Butts Hemorrhoid (lidocaine5% phenylephrine hcl 0.25% hemorrhoid) ointment is adults: When practical, cleanse the affected area with mild soap and warm water, rinse thoroughly, and gently dry. This formulation utilizes a ointment delivery system. Marketed by Jiangxi Yudexi Pharmaceutical Co., Ltd, this product is identified by NDC 85248-018 and is authorized under FDA application M015.
Identification & Billing
- RxCUI: 2672354 - lidocaine 5 % / phenylephrine HCl 0.25 % Rectal Ointment
- RxCUI: 2672354 - lidocaine 0.05 MG/MG / phenylephrine hydrochloride 0.0025 MG/MG Rectal Ointment
- RxCUI: 2672354 - lidocaine 5 % / phenylephrine hydrochloride 0.25 % Rectal Ointment
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Amide Local Anesthetic - [EPC] (Established Pharmacologic Class)
- Amides - [CS]
- Antiarrhythmic - [EPC] (Established Pharmacologic Class)
- Local Anesthesia - [PE] (Physiologic Effect)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 85248 - Jiangxi Yudexi Pharmaceutical Co., Ltd
- 85248-018 - Dr.seymour Butts Hemorrhoid
- 85248-018-01 - 30 g in 1 TUBE
- 85248-018 - Dr.seymour Butts Hemorrhoid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 85248-018-01 identifies a specific commercial package of 30 g in 1 tube of Dr.seymour Butts Hemorrhoid, a human over the counter drug labeled by Jiangxi Yudexi Pharmaceutical Co., Ltd. This ointment is formulated for topical use and contains lidocaine; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Jiangxi Yudexi Pharmaceutical Co., Ltd on January 29, 2026. The current certification is valid through December 31, 2027.
How is this Jiangxi Yudexi Pharmaceutical Co., Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 85248001801. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.